Tesmec SpA
MIL:TES
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Tesmec SpA
MIL:TES
|
IT |
|
T
|
Takeda Pharmaceutical Co Ltd
XBER:TKD
|
JP |
|
M
|
Muenchener Rueckversicherungs Gesellschaft in Muenchen AG
LSE:0KFE
|
DE |
|
Curro Holdings Ltd
F:24P
|
ZA |
|
B
|
Balchem Corp
XBER:BL9B
|
US |
|
Eagle Bancorp Montana Inc
NASDAQ:EBMT
|
US |
|
S
|
Sino Land Co Ltd
F:SNO
|
HK |
Wall St Price Targets
TES Price Targets Summary
Tesmec SpA
According to Wall Street analysts, the average 1-year price target for TES is 0.4692 EUR with a low forecast of 0.4646 EUR and a high forecast of 0.483 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is TES's stock price target?
Price Target
0.4692
EUR
According to Wall Street analysts, the average 1-year price target for TES is 0.4692 EUR with a low forecast of 0.4646 EUR and a high forecast of 0.483 EUR.
What is the Revenue forecast for Tesmec SpA?
Projected CAGR
10%
Over the last 14 years, the compound annual growth rate for Revenue has been 6%. The projected CAGR for the next 3 years is 10%.
What is the Operating Income forecast for Tesmec SpA?
Projected CAGR
28%
Over the last 14 years, the compound annual growth rate for Operating Income has been 3%. The projected CAGR for the next 3 years is 28%.
What is the Net Income forecast for Tesmec SpA?
Projected CAGR
125%
Over the last 14 years, the compound annual growth rate for Net Income has been -9%. The projected CAGR for the next 3 years is 125%.
